Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation

Thrombosis and Haemostasis

Volumn 112, Issue 4, 2014, Pages 781-788

  Roldán, Vanessa ^a   Arroyo, Ana Belen ^a   Salloum Asfar, Sallam ^a   Manzano Fernández, Sergio ^b   García Barberá, Nuria ^a   Marín, Francisco ^b   Vicente, Vicente ^a   González Conejero, Rocío ^a   Martínez, Constantino ^a  

^a HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Atrial fibrillation; Cardiovascular event; Inflammation; Mir 146a 5p

Indexed keywords

ACENOCOUMAROL; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 6; MICRORNA 146A; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; LIPOPOLYSACCHARIDE; MESSENGER RNA; MICRORNA; MIRN146 MICRORNA, HUMAN;

AGED; ALLELE; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPING TECHNIQUE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; ATRIAL FIBRILLATION; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; COHORT ANALYSIS; COMPLICATION; CYTOLOGY; GENETICS; INFLAMMATION; METABOLISM; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PREDICTIVE VALUE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICRORNAS; MONOCYTES; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, MESSENGER;

EID: 84908541895     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-01-0092     Document Type: Article

References (47)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–988
2. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155–166
3. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021–2028
4. Patel P, Dokainish H, Tsai P, et al. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol 2010; 21: 1064–1070
5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–867
6. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864–2870
7. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe? Thromb Haemost 2010; 104: 45–48
8. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor- based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272
9. Roldan V, Marin F, Diaz J, et al. High sensitivity cardiac troponin T and interleukin- 6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 2012; 10: 1500–1507
10. MacCallum PK, Rudnicka AR, Rumley A, et al. Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. Br J Haematol 2004; 127: 448–450
11. Pardali E, Waltenberger J. Monocyte function and trafficking in cardiovascular disease. Thromb Haemost 2012; 108: 804–811
12. Jover E, Marin F, Roldan V, et al. Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease. Ann Med 2013; 45: 274–290
13. Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. Thromb Haemost 2010; 104: 657–663
14. Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438–444
15. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012; 60: 2263–2270
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297
17. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233
18. Wang Z, Lu Y, Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res 2011; 89: 710–721
19. Martin K, O’Sullivan JF, Caplice NM. New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture. Curr Opin Cardiol 2011; 26: 569–575
20. Taganov KD, Boldin MP, Chang KJ, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481–12486
21. Jin J, Samuvel DJ, Zhang X, et al. Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells. Mol Immunol 2011; 49: 423–432
22. Lofgren SE, Frostegard J, Truedsson L, et al. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun 2012; 13: 268–274
23. Jeon YJ, Kim OJ, Kim SY, et al. Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction risk. Arterioscler Thromb Vasc Biol 2013; 33: 420–430
24. Ramkaran P, Khan S, Phulukdaree A, et al. miR-146a Polymorphism Influences Levels of miR-146a, IRAK-1, and TRAF-6 in Young Patients with Coronary Artery Disease. Cell Biochem Biophys 2014; 68: 259-266
25. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870–947
26. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551–2567
27. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–1847
28. Pencina MJ, D’Agostino RB, Sr., D’Agostino RB, Jr., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172
29. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115–126
30. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta 2012; 413: 3–14
31. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129–2138
32. Roldan V, Marin F, Muina B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57: 2496–2504
33. Harley JB, Alarcon-Riquelme ME, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40: 204–210
34. Luo X, Yang W, Ye DQ, et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 2011; 7: e1002128
35. Chen HF, Hu TT, Zheng XY, et al. Association between miR-146a rs2910164 polymorphism and autoimmune diseases susceptibility: a meta-analysis. Gene 2013; 521: 259–264
36. Jazdzewski K, Murray EL, Franssila K, et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 2008; 105: 7269–7274
37. Xu Y, Li L, Xiang X, et al. Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: A systematic review and meta-analysis. Gene 2013; 527: 584–593
38. Wang X, Ha T, Liu L, et al. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc Res 2013; 97: 432–442
39. Nahid MA, Satoh M, Chan EK. Mechanistic role of microRNA-146a in endotoxin- induced differential cross-regulation of TLR signaling. J Immunol 2011; 186: 1723–1734
40. Stachon P, Missiou A, Walter C, et al. Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans. PLoS One 2010; 5: e11589
41. Zhao JL, Rao DS, O’Connell RM, et al. MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice. Elife 2013; 2: e00537
42. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343–1345
43. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97: 1490–1493
44. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172–1187
45. Nahid MA, Pauley KM, Satoh M, et al. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J Biol Chem 2009; 284: 34590–34599
46. Cheng HS, Sivachandran N, Lau A, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med 2013; 5: 1017–1034
47. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84–91.